UroGen Pharma (URGN) News Today $3.93 -0.26 (-6.21%) Closing price 04:00 PM EasternExtended Trading$3.97 +0.04 (+1.02%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why is UroGen Pharma Dropping Today?UroGen Pharma Ltd. (NASDAQ:URGN) shares have decreased today amid a mix of clinical setbacks and heightened legal scrutiny, partially offset by marginally improved analyst forecasts. HC Wainwright raised its Q2 2025 EPS estimate to (-$0.74) from (-$0.75) and lifted its full-year EPS outlook, signaling a slightly better earnings trajectory. Multiple law firms—including Levi & Korsinsky, Pomerantz, and Bronstein, Gewirtz & Grossman—have launched investigations into potential securities‐fraud and investor claims against the company. Short interest data showed effectively zero shares short with a days‐to‐cover ratio of 0.0, indicating no meaningful change in bearish positioning. The FDA’s Oncologic Drugs Advisory Committee voted against the risk/benefit profile of UroGen’s late‐stage bladder cancer therapy UGN-102, triggering a 44% share collapse on May 21. Guggenheim lowered its price target on URGN to $15.00, citing reduced confidence in the company’s approval timeline and commercial prospects. Posted 32m agoAI Generated. May Contain Errors. URGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens BermanMay 27 at 3:14 PM | globenewswire.comQ2 EPS Estimates for UroGen Pharma Raised by HC WainwrightUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of UroGen Pharma in a research note issued to investors on Thursday, May 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will earnMay 27 at 1:18 AM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Price Target Cut to $15.00 by Analysts at GuggenheimMay 26 at 1:59 AM | americanbankingnews.comUroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer DrugMay 25 at 2:16 PM | benzinga.comGuggenheim Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $15.00Guggenheim dropped their price target on UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research report on Friday.May 25 at 11:05 AM | marketbeat.comOngoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky InvestigatesMay 25 at 5:33 AM | markets.businessinsider.comUroGen Pharma (NASDAQ:URGN) Rating Lowered to "Neutral" at HC WainwrightMay 25 at 2:11 AM | americanbankingnews.comUroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens BermanMay 24 at 4:19 PM | morningstar.comUroGen Pharma (NASDAQ:URGN) Price Target Cut to $3.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group reduced their price objective on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday.May 24 at 10:49 AM | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for UroGen Pharma (NASDAQ:URGN)HC Wainwright restated a "neutral" rating on shares of UroGen Pharma in a research note on Thursday.May 24 at 8:10 AM | marketbeat.comKaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)May 23, 2025 | theglobeandmail.comHC Wainwright & Co. Downgrades UroGen Pharma (URGN)May 23, 2025 | msn.comPoint72 Asset Management L.P. Sells 1,189,532 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Point72 Asset Management L.P. trimmed its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 79.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 317,114 shares of the company's stock after selling 1,189,532 shares durinMay 23, 2025 | marketbeat.comUroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens BermanMay 22, 2025 | globenewswire.com1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion BankToronto Dominion Bank acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,749,142 shares of the company's stock, valued at approximately $18,62May 22, 2025 | marketbeat.comUroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s UnruffledMay 21, 2025 | msn.comWhat's Going On With UroGen Pharma Stock Wednesday?May 21, 2025 | benzinga.comUroGen crashes as FDA AdCom rebukes bladder cancer drugMay 21, 2025 | msn.comUroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, EitherMay 21, 2025 | seekingalpha.comINVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLCMay 21, 2025 | globenewswire.comUroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)May 21, 2025 | businesswire.comVestal Point Capital LP Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Vestal Point Capital LP raised its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 307.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,630,000 shares of the company's stock after purchasing an additional 1,230,000 shaMay 21, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNMay 20, 2025 | prnewswire.comStonepine Capital Management LLC Raises Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Stonepine Capital Management LLC boosted its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 15.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 324,324 shares of the company's stock after buying an additionaMay 20, 2025 | marketbeat.comSecurities Fraud Investigation Into UroGen Pharma Ltd. ...May 19, 2025 | gurufocus.comSecurities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmMay 19, 2025 | businesswire.comRTW Investments LP Has $40.84 Million Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)RTW Investments LP lifted its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,834,794 shares of the company's stock after purchasing an addMay 18, 2025 | marketbeat.comHC Wainwright Forecasts Stronger Earnings for UroGen PharmaUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Investment analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for shares of UroGen Pharma in a research report issued on Tuesday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings pMay 17, 2025 | marketbeat.comHC Wainwright Increases Earnings Estimates for UroGen PharmaMay 17, 2025 | americanbankingnews.comSecurities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 16, 2025 | tmcnet.comSecurities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R.May 16, 2025 | businesswire.comUroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study DisagreementMay 16, 2025 | marketwatch.comUroGen stock tumbles on FDA efficacy concernsMay 16, 2025 | investing.comINVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLCMay 16, 2025 | globenewswire.com233,322 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Hudson Bay Capital Management LPHudson Bay Capital Management LP purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 233,322 shares of the company's stock,May 16, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of UroGen Pharma in a research report on Tuesday.May 15, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target PriceMay 15, 2025 | finance.yahoo.comUroGen Pharma (NASDAQ:URGN) Shares Gap Down After Earnings MissUroGen Pharma (NASDAQ:URGN) Shares Gap Down Following Weak EarningsMay 14, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPSUroGen Pharma (NASDAQ:URGN - Get Free Report) posted its earnings results on Monday. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09).May 14, 2025 | marketbeat.comEarnings call transcript: UroGen Pharma Q1 2025 reveals revenue miss, stock edges upMay 14, 2025 | uk.investing.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comUroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...May 13, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comUroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 12, 2025 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Position Reduced by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC reduced its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 45.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,100 shares of thMay 12, 2025 | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for UroGen Pharma (NASDAQ:URGN)D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday.May 10, 2025 | marketbeat.comDAFNA Capital Management LLC Increases Position in UroGen Pharma Ltd. (NASDAQ:URGN)DAFNA Capital Management LLC boosted its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 7.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 492,515 shares of the company's stoMay 10, 2025 | marketbeat.comA Look at UroGen Pharma's Upcoming Earnings ReportMay 9, 2025 | benzinga.comUroGen Pharma Q1 Earnings PreviewMay 9, 2025 | msn.comUroGen's bladder cancer treatment to be reviewed by FDA advisory committeeMay 7, 2025 | msn.com Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.071.02▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼294▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Structure Therapeutics News Today Janux Therapeutics News Today Evotec News Today ARS Pharmaceuticals News Today Adaptive Biotechnologies News Today Vera Therapeutics News Today Dyne Therapeutics News Today ANI Pharmaceuticals News Today Qilian International Holding Group News Today Ocular Therapeutix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts